| Annual Financials | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 11 | 7 | 16 | 26 | 0 |
| Expenses | 10 | 5 | 13 | 20 | 0 |
| EBITDA | 1 | 2 | 3 | 6 | 0 |
| Operating Profit % | -4 % | 23 % | 16 % | 22 % | 0 % |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 1 | 1 | 1 | 0 |
| Profit Before Tax | 0 | 1 | 2 | 5 | 0 |
| Tax | 0 | 0 | 1 | 1 | 0 |
| Net Profit | 0 | 1 | 1 | 4 | 0 |
| EPS in ₹ | 11.62 | 1.89 | 2.37 | 6.14 | 0.00 |
Asston Pharmaceuticals
Asston Pharmaceuticals
100.00
+13.90
(16.14%)
Market Cap
₹85.02 Cr
PE Ratio
-
Volume
82,000.00
Day High - Low
₹100.00 - ₹87.94
52W High-Low
₹126.00 - ₹75.21
Key Fundamentals
Market Cap
85.02 Cr
EPS
6.14
PB Ratio
-
Book Value
45.35
EBITDA
6.00
Dividend Yield
0.00 %
Industry
Capital Goods Sector
Other Electrical Equipment ROE Growth %
-
Debt to Equity
0.77
Actual
Company News
View All News
Asston Pharmaceuticals Approves Capacity Expansion and Half-Year ResultsNov 14, 2025
Asston Pharmaceuticals' Board approved unaudited financial statements for the half-year ended September 30, 2025, and capacity expansion through a new manufacturing unit (Unit No. II) in Ambernath, Maharashtra. The company plans to invest approximately Rs 600 lakhs to increase total capacity to 14-15 crore tablets per month by Q4 2025-26, funded through internal accruals and IPO proceeds.
Asston Pharmaceuticals Appoints Key Personnel and Approves Loan Facilities Worth Rs 5.7 Crore
Oct 16, 2025
Oct 16, 2025Asston Pharmaceuticals Limited's board approved multiple key appointments on October 16, 2025. The company appointed Mr. Yogesh Supekar as Additional Non-Executive Non-Independent Director, bringing 24 years of finance experience across banking, media, and public relations sectors. Mr. Rishi Upadhaya was named Company Secretary and Compliance Officer, while M/s Yash A. Jain & Associates was appointed as internal auditor for FY 2025-2026. The board also approved two loan facilities: an interest-free unsecured loan of up to Rs 3 crore from company directors, and a secured loan facility of up to Rs 2.7 crore from HDFC Bank for purchasing commercial space. All appointees are independent of existing directors, and Mr. Supekar is not debarred from holding directorship positions.
Deven Manohar Patil has resigned from his position as Chief Financial Officer of Asston Pharmaceuticals Limited, effective October 13, 2025. The resignation was submitted to pursue new career opportunities outside the company. His last working day was October 13, 2025, at the close of business hours. The Board of Directors received his resignation letter on the same date. Saili Jayaram More, Whole Time Director, signed the regulatory disclosure documents.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
3,286.20 | #1 94,407.00 | 33.31 | 14,846.10 | 27.62 | #1 1,928 | 133.75 | 46.02 | |
981.40 | 44,239.00 | 37.83 | 6,652.10 | 109.76 | 937 | 71.64 | 39.23 | |
9,156.50 | 36,780.12 | 39.43 | #1 18,680.60 | 15.07 | 821 | 29.81 | 56.96 | |
210.63 | 14,582.86 | 43.66 | 2,360.30 | 147.31 | 369 | - | - | |
323.05 | 9,824.32 | 22.24 | 2,524.60 | 98.10 | 295 | 72.08 | 45.72 | |
269.60 | 9,751.89 | 29.30 | 3,459.50 | 37.06 | 140 | #1 1,636.49 | 20.52 | |
991.80 | 6,616.69 | 77.10 | 1,115.20 | 26.44 | 63 | 42.86 | 40.75 | |
413.80 | 5,259.61 | #1 17.08 | 2,192.50 | 99.83 | 214 | 36.39 | 34.28 | |
2,577.15 | 5,236.55 | 34.58 | 998.10 | #1 158.71 | 159 | -84.86 | 37.97 | |
4,128.90 | 4,723.54 | 27.56 | 639.60 | 56.11 | 147 | 40.37 | - |
Growth Rate
Revenue Growth
62.03 %
Net Income Growth
178.57 %
Cash Flow Change
99.24 %
ROE
64.05 %
ROCE
32.28 %
EBITDA Margin (Avg.)
32.64 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 10 | 14 | 20 | 28 |
| Fixed Assets | 1 | 1 | 1 | 1 |
| Current Assets | 7 | 11 | 18 | 27 |
| Capital Work in Progress | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 9 | 13 | 19 | 27 |
| Total Liabilities | 10 | 14 | 20 | 28 |
| Current Liabilities | 8 | 10 | 12 | 15 |
| Non Current Liabilities | 1 | 2 | 2 | 2 |
| Total Equity | 1 | 2 | 6 | 11 |
| Reserve & Surplus | 0 | 1 | 6 | 5 |
| Share Capital | 1 | 1 | 1 | 6 |
Cash Flow
| Cash Flow | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 0 | -0 | 0 |
| Investing Activities | 0 | -1 | 0 | 1 |
| Operating Activities | -1 | -0 | -4 | 0 |
| Financing Activities | 1 | 1 | 4 | -1 |
Share Holding
| % Holding | Jan 2025 | Jun 2025 | Jul 2025 | Sept 2025 |
| Promoter | 69.07 % | 50.66 % | 68.76 % | 50.66 % |
| FIIs | 0.00 % | 9.70 % | 0.00 % | 6.04 % |
| DIIs | 0.00 % | 4.08 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 30.95 % | 0.00 % | 37.06 % |
| Others | 30.93 % | 4.61 % | 31.24 % | 6.24 % |
| No of Share Holders | 104 | 662 | 128 | 751 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 29 Sept 2025 |  Annual General Meeting | NA | 29 Sept 2025 | 102.45 | 96.13 |
| 14 Nov 2025 |  Quarterly Result Announcement | NA | 14 Nov 2025 | 77.10 | 77.60 |
Announcements
Regulation 30 SEBI (LODR) Regulation Update.Nov 14, 2025
Nov 14, 2025Unaudited Financial Results For The Half Year Ended 30Th September 2025 Along With A Limited Review ReportNov 14, 2025
Nov 14, 2025Board Meeting Outcome for Outcome Of Board MeetingNov 14, 2025
Nov 14, 2025Board Meeting Intimation for Intimation Of Board MeetingNov 11, 2025
Nov 11, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 17, 2025
Oct 17, 2025General AnnouncementOct 16, 2025
Oct 16, 2025Meeting UpdatesOct 16, 2025
Oct 16, 2025Appointment of Company Secretary and Compliance OfficerOct 16, 2025
Oct 16, 2025Board Meeting Outcome for Outcome Of Board Meeting Scheduled To Be Held On 16Th October 2025Oct 16, 2025
Oct 16, 2025Board Meeting Intimation for Intimitation Of Board Meeting Schedule To Be Held On 16Th October 2025Oct 13, 2025
Oct 13, 2025Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)Oct 13, 2025
Oct 13, 2025Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerOct 13, 2025
Oct 13, 2025Announcement under Regulation 30 (LODR)-Meeting UpdatesOct 01, 2025
Oct 01, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 01, 2025
Oct 01, 2025Closure of Trading WindowSep 30, 2025
Sep 30, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 29, 2025
Sep 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 08, 2025
Sep 08, 2025Reg. 34 (1) Annual Report.Sep 06, 2025
Sep 06, 2025NOTICE AND INTIMATION OF 6TH AGM SCHEDULED ON 29 SEPTEMBER 2025Sep 06, 2025
Sep 06, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderSep 02, 2025
Sep 02, 2025Pursuant To The Provisions Of Regulation 42 Of SEBI (Listing Obligation And Disclosure Requirement) Regulation 2015Aug 25, 2025
Aug 25, 2025Board Meeting Outcome for OUTCOME OF THE BOARD MEETING HELD TODAY I.E. MONDAY AUGUST 25 2025Aug 25, 2025
Aug 25, 2025Board Meeting Intimation for Regulation 29 Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations 2015.Aug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJul 23, 2025
Jul 23, 2025Listing of Equity Shares of Asston Pharmaceuticals LtdJul 16, 2025
Jul 16, 2025Technical Indicators
RSI(14)
Neutral 51.39
ATR(14)
Volatile 3.47
STOCH(9,6)
Neutral 72.17
STOCH RSI(14)
Overbought 86.61
MACD(12,26)
Bullish 1.32
ADX(14)
Weak Trend 20.62
UO(9)
Bearish 51.65
ROC(12)
Uptrend And Accelerating 10.83
WillR(14)
Neutral -23.79
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
